Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorRadboud University Medical Center

About this trial

The goal of this clinical trial is to investigate the feasibility if a remotely administered smartphone app can increase the volume and intensity of physical activity in daily life in patients with isolated Rapid Eye Movement (REM) sleep behaviour disorder over a long period of time (24 months).

Participants will be tasked to achieve an incremental increase of daily steps (volume) and amount of minutes exercised at a certain heart rate (intensity) with respect to their own baseline level. Motivation with regards to physical activity will entirely be communicated through the study specific Slow Speed smartphone app. Primary outcomes will be compliance expressed as longitudinal change in digital measures of physical activity (step count) measured using a Fitbit smartwatch. Exploratory outcomes entail retention rate, completeness of remote digital biomarker assessments, digital prodromal motor and non-motor features of PD, blood biomarkers and brain imaging markers. Using these biomarkers, we aim to develop a composite score (prodromal load score) to estimate the total prodromal load. An international exercise study with fellow researchers in the United States and United Kingdom are currently in preparation (Slow-SPEED). Our intention is to analyse overlapping outcomes combined where possible through a meta-analysis plan, to obtain insight on (determinants of) heterogeneity in compliance and possible efficacy across subgroups

Eligibility criteria

Qualifiers

previously diagnosed with iRBD meeting the following criteria according to the International Classification of Sleep Disorders (ICSD-3)

able to understand the Dutch language

being able to walk independently inside the home without the use of a walking aid

Not in a high physical activity range during the 4-week eligibility and baseline period

Disqualifiers

clinically diagnosed or self-reported diagnosis neurodegenerative disease;

self-reported weekly falls in the previous 3 months;

dexterity problems or cognitive impairments hampering smartphone use;

if they do not wish to be informed about an increased risk of developing diseases associated with iRBD

Trial design

Treatments tested in this trial

  • Increase of physical activity volume and intensity with the use of a motivational smartphone application

Treatment groups

110 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Radboud University Medical Center

Lead sponsor

Stichting ParkinsonNL

Collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

Collaborator

Michael J. Fox Foundation for Parkinson's Research

Collaborator

Parkinson's UK

Collaborator

Cure Parkinson's

Collaborator

Edmond J. Safra Foundation

Collaborator

Davis Phinney Foundation

Collaborator

Donders Centre for Cognitive Neuroimaging

Collaborator

Anne Wojcicki Foundation

Collaborator

Sleep Medicine Centre Kempenhaeghe

Collaborator

Sleep Medicine Centre SEIN

Collaborator

Queen Mary University of London

Collaborator

23andMe, Inc.

Collaborator

Parkinsons Progression Markers Initiative (PPMI)

Collaborator

Massachusetts General Hospital

Collaborator

Harvard School of Public Health (HSPH)

Collaborator

IJsfontein B.V., Netherlands

Collaborator

Hoffmann-La Roche

Collaborator

Erasmus Medical Center

Collaborator

University of Illinois at Chicago

Collaborator

University of Rochester

Collaborator

University of Bristol

Collaborator

University of Plymouth

Collaborator

University of Luebeck

Collaborator

McGill University

Collaborator

University of Pittsburgh

Collaborator